145 related articles for article (PubMed ID: 12961050)
1. Efficacy, safety and cost of new cardiovascular drugs: a survey.
Garattini S; Bertele' V
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):701-6. PubMed ID: 12961050
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and cost of new drugs acting on the central nervous system.
Garattini S; Bertele' V
Eur J Clin Pharmacol; 2003 May; 59(1):79-84. PubMed ID: 12743674
[TBL] [Abstract][Full Text] [Related]
3. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
4. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
5. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
Ainsworth MA
Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
[TBL] [Abstract][Full Text] [Related]
6. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.
Hartmann M; Mayer-Nicolai C; Pfaff O
Crit Rev Oncol Hematol; 2013 Aug; 87(2):112-21. PubMed ID: 23433721
[TBL] [Abstract][Full Text] [Related]
7. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
van Luijn JC; Gribnau FW; Leufkens HG
Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
[TBL] [Abstract][Full Text] [Related]
8. Drug lag for cardiovascular drug approvals in India compared with the US and EU approvals.
Kataria BC; Mehta DS; Chhaiya SB
Indian Heart J; 2013; 65(1):24-9. PubMed ID: 23438609
[TBL] [Abstract][Full Text] [Related]
9. Use of the conditional marketing authorization pathway for oncology medicines in Europe.
Hoekman J; Boon WP; Bouvy JC; Ebbers HC; de Jong JP; De Bruin ML
Clin Pharmacol Ther; 2015 Nov; 98(5):534-41. PubMed ID: 26080745
[TBL] [Abstract][Full Text] [Related]
10. Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use.
Impicciatore P; Choonara I
Br J Clin Pharmacol; 1999 Jul; 48(1):15-8. PubMed ID: 10383554
[TBL] [Abstract][Full Text] [Related]
11. New safe medicines faster: A proposal for a key action within the European union's 6th framework programme.
Bjerrum OJ
Pharmacol Toxicol; 2000; 86 Suppl 1():23-6. PubMed ID: 10905750
[TBL] [Abstract][Full Text] [Related]
12. Future European health care: cost containment, health care reform and scientific progress in drug research.
Emilien G
Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
[TBL] [Abstract][Full Text] [Related]
13. Ophthalmic medicine regulatory approvals through the European Centralised Procedure, 1999-2017: Clinical efficacy considerations.
Morgan-Warren PJ
Eur J Ophthalmol; 2020 Mar; 30(2):321-349. PubMed ID: 30832499
[TBL] [Abstract][Full Text] [Related]
14. European regulatory use and impact of subgroup evaluation in marketing authorisation applications.
Tanniou J; Teerenstra S; Hassan S; Elferink A; van der Tweel I; Gispen-de Wied C; Roes KCB
Drug Discov Today; 2017 Dec; 22(12):1760-1764. PubMed ID: 28943304
[TBL] [Abstract][Full Text] [Related]
15. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
16. European Medicines Agency Perspective on Oncology Study Design for Marketing Authorization and Beyond.
Jonsson B; Martinalbo J; Pignatti F
Clin Pharmacol Ther; 2017 May; 101(5):577-579. PubMed ID: 28073148
[TBL] [Abstract][Full Text] [Related]
17. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
Timur A; Picone G
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
[TBL] [Abstract][Full Text] [Related]
19. Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe.
Davis C; Wagner AK; Salcher-Konrad M; Scowcroft H; Mintzes B; Pokorny AMJ; Lew J; Naci H
BMJ; 2023 Mar; 380():e073711. PubMed ID: 36990506
[TBL] [Abstract][Full Text] [Related]
20. Discontinued drugs in 2008: cardiovascular drugs.
Zhang XS; Xiang BR
Expert Opin Investig Drugs; 2009 Jul; 18(7):875-85. PubMed ID: 19548849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
